UNH · UnitedHealth Group
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $355
Note written ·
Price against the kill line
14.8% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $355.00, on record since 10 November 2026. The shares are up 3.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $355, under the 200-day moving average and well beneath where the shares traded before the 13 October 2026 third-quarter report, which would erase the post-earnings gain. Separately, 2027 adjusted EPS guidance below the lower end of the 13%–16% long-term growth range would break the operating case.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 3 November 2026; valuation at the 13 November 2026 close
- Net income, latest quarter ($M)
- 4,110
- Net income, four quarters ($M)
- 15,884
- Shareholders' equity ($M)including non-controlling interests
- 104,129
- Price to earnings (×)
- 23.0
- Price to book value (×)
- 3.5
- Revenue, latest quarter ($M)total revenues, including investment gains and losses
- 112,694
- Revenue, change on a year (%)
- −0.4
- Market value ($M)
- 365,093
UnitedHealth Group is an insurer: net cash, enterprise value and free cash flow are not shown, because a bank's or insurer's cash and investments back its deposits and policies.
All filed numbers
What UnitedHealth Group reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 112,694 | −0.4 | 87.8 | 5.8 |
| first filed | 112,032 | +0.4 | 88.1 | 7.1 |
| first filed | 111,721 | +2.0 | 88.5 | 8.0 |
| first filed | 113,215 | +12.3 | 88.8 | 0.3 |
| first filed | 113,161 | +12.2 | 88.9 | 3.8 |
| first filed | 111,616 | +12.9 | 88.3 | 4.6 |
| Pre-tax income ($M) | 5,524 |
| Net income ($M) four quarters: 15,884 | 4,110 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −0.7 |
| Operating cash flow ($M) | 26,195 |
| Capital spending ($M) | 3,369 |
| Free cash flow ($M) | Not meaningful |
Not meaningful: a bank's or insurer's operating cash flow moves with its deposits, loans and policy reserves, so it is not cash free for its owners.
| Cash and short-term investments ($M) | 28,549 |
| Debt ($M) non-current long-term debt plus current debt | 74,331 |
| Net cash, cash less debt ($M) | Not meaningful |
| Deferred revenue ($M) +0.9% on a year | 3,397 |
| Backlog, orders not yet delivered ($M) −12.1% on a year | 10,200 |
| Receivables ($M) | 20,543 |
| Inventory ($M) at 31 December 2025, filed 2 March 2026 | 3,300 |
| Shareholders' equity ($M) including non-controlling interests | 104,129 |
Not meaningful: a bank's or insurer's cash and investments back its deposits and policies.
| Market value ($M) | 365,093 |
| Enterprise value, market value plus net debt ($M) | Not meaningful |
| Enterprise value to sales (×) | Not meaningful |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | 23.0 |
| Price to book value (×) | 3.5 |
| Free-cash-flow yield (%) | Not meaningful |
Not meaningful: a bank's or insurer's cash and investments back its deposits and policies.
Not meaningful: a bank's or insurer's operating cash flow moves with its deposits, loans and policy reserves, so it is not cash free for its owners.
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 1.6% of shares outstanding sold short, 2.0 days of average trading to cover, −12.2% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $456K |
| 12 monthsfrom | $0 | $945K |
The thesis
UnitedHealth Group's earnings recovery gives the shares a modest edge over the S&P 500. Two facts carry it: 2026 adjusted earnings per share (EPS) guided to at least $20.50, and a buyback widened by up to 50 million shares. The Medicare enrollment close on 7 December 2026 and the 2027 outlook due with the fourth-quarter report in late January settle whether the recovery carries into next year.
The operating evidence rests on the third-quarter report. Adjusted EPS was $4.69, up from $2.92 a year earlier. The medical care ratio (MCR, the share of premiums paid out in claims) improved to 88.4% from 89.9% (Form 8-K, 13 October 2026). On the earnings call, management said its 2027 EPS forecast starts from the lower end of its 13%–16% long-term growth range (Benzinga, 13 October 2026).
The price reflects the 2026 guidance raise but not yet a 2027 return to that growth range. The shares closed at $405.13 on 12 November 2026, 12.2% below the 52-week high of $461.62 set on 16 July 2026 and below Fintel's $481.06 average analyst target of 6 November 2026. The rating is Medium because the cost relief is confirmed across the industry, while Medicare Advantage membership losses and legal pressure remain open.
Bullish and bearish views on UnitedHealth Group Incorporated
The bull case on UnitedHealth Group Incorporated (UNH), in brief: the buyback authorization grew. The bear case: reserve releases flattered the results.
Bull case
- The buyback authorization grew. In November 2026 the board amended the repurchase program to cover up to 50 million more shares, with no expiration date. Only 7.2 million shares were left under the old authorization at 30 September 2026, and 896,022,611 shares were outstanding at 30 October 2026 (Form 10-Q).
- The company bought above today's price. The 10-Q shows 3.4 million shares repurchased in the third quarter at an average of $410.01, above the $405.13 close of 12 November 2026.
- The 2026 outlook went up again. The 13 October 2026 release raised 2026 guidance to at least $20.50 of adjusted EPS, from $19.50–$20.00 (Form 8-K).
- Optum's margins widened sharply. Optum's third-quarter operating earnings rose to $3.7 billion from $2.5 billion, and its operating margin rose to 5.6% from 3.6% (Form 8-K, 13 October 2026).
- Insurance profits recovered. UnitedHealthcare's third-quarter operating earnings rose to $2.8 billion from $1.8 billion (Form 8-K, 13 October 2026). Chief executive Tim Noel said Medicaid margins bottomed in 2026 (Benzinga, 13 October 2026).
- Peers confirm the cost relief. Elevance Health raised 2026 adjusted EPS guidance to at least $29.00 on 21 October 2026. Humana raised its own to at least $9.50 on 6 November 2026 and said cost trend is running at the lower end of its 7%–8% range (Healthcare Dive).
- Cash returns continue. The board declared a quarterly dividend of $2.32 per share on 4 November 2026 (company news).
- Optum is still bidding for growth. Bloomberg reported on 9 November 2026 that UnitedHealth offered $28 per share in cash for Surgery Partners, above the $25 agreed sale price to HealthSpan Partners (Becker's ASC). UnitedHealth declined to comment.
Bear case
- Reserve releases flattered the results. The 10-Q reports $1,440 million of favorable prior-year reserve development over nine months, including $610 million in the third quarter, and credits a mild respiratory illness season. Gains of that kind do not repeat every quarter.
- Revenue is shrinking. Third-quarter revenue was $112.7 billion against $113.2 billion a year earlier (Form 8-K, 13 October 2026), as the company exits unprofitable products.
- Medicare members and networks are leaving. UnitedHealthcare's Medicare Advantage membership fell by 935,000 from year-end 2025 (Form 8-K, 13 October 2026). Lee Health in Florida said on 9 November 2026 that it will end its UnitedHealthcare contract effective 31 December 2026, and UnitedHealthcare is discontinuing a supplemental Medicare plan in Wyoming (company news, 10 November 2026).
- A stronger rival is gaining members. Humana said on 6 November 2026 that new-member sign-ups are above plan and that 93% of its members will be in plans rated four stars or higher in 2027, up from 41% in 2026 (Healthcare Dive). UnitedHealthcare enters 2027 under lower star ratings.
- Deals face regulatory friction. The Surgery Partners special committee rejected the $28 offer on 9 November 2026, citing greater regulatory risk and a longer closing timeline (Becker's ASC). Senator Elizabeth Warren attacked the $3.3 billion Amedisys deal on 2 November 2026 (Benzinga).
- Legal and political pressure keeps building. Department of Justice investigations into Medicare Advantage practices remain open, and Texas Attorney General Ken Paxton opened a state investigation on 5 October 2026. Senate Democrats opened an inquiry on 10 November 2026 into ten insurers, including UnitedHealthcare, over Affordable Care Act coverage terminations.
Price setup
The shares closed at $405.13 on 12 November 2026, up from $394.15 on 6 November 2026. They sit above the 50-day moving average of $391.01 and the 200-day moving average of $363.0, both as of 12 November 2026. The 3-month change is 1.5%, measured from the 14 August 2026 close.
The range is wide. The 52-week closing low was $259.02 on 27 March 2026, and the 52-week intraday high was $461.62 on 16 July 2026. The shares have held most of the post-report gain from 13 October 2026, when they rose about 4% to $395.19 in the morning session (24/7 Wall St).
Above, the $410.01 average price the company paid for its own shares in the third quarter (Form 10-Q) is the nearest reference. The company is retiring shares, not issuing them. No earnings report falls before late January, so enrollment results and network news drive the shares until then.
Catalysts ahead
- 7 December 2026: Medicare annual enrollment period closes (opened 15 October 2026). Sets 2027 UnitedHealthcare Medicare Advantage membership under lower star ratings and network departures, after a 935,000-member decline in 2026 and with Humana reporting sign-ups ahead of plan.
- 31 December 2026: Lee Health's termination of its UnitedHealthcare contract takes effect. Shows whether provider-network attrition in Florida continues into 2027 or a new agreement is reached.
- ~26 January 2027 (est.): Fourth-quarter 2026 report and 2027 outlook (prior-year report came on 27 January 2026; date not yet announced). Tests whether 2027 EPS guidance starts at or above the lower end of the 13%–16% growth range, and whether the medical care ratio holds without reserve releases.
What would change the view
A daily close below $355, under the 200-day moving average and well beneath where the shares traded before the 13 October 2026 third-quarter report, which would erase the post-earnings gain. Separately, 2027 adjusted EPS guidance below the lower end of the 13%–16% long-term growth range would break the operating case.
The risks this note tracks, each with what would confirm it:
- Higher-rated rivals such as Humana take Medicare Advantage share during the 2027 enrollment season. Confirmed by: UnitedHealth disclosing a 2027 Medicare Advantage decline larger than the 935,000 members lost in 2026 while Humana reports 2027 membership growth.
- The medical-cost improvement leans on reserve releases while care intensity stays above historical norms. Confirmed by: a fourth-quarter medical care ratio above Q3's 88.4% with little or no favorable prior-period reserve development.
- The 2027 earnings outlook falls short of the growth framing given on the Q3 call. Confirmed by: 2027 adjusted EPS guidance below the lower end of the 13%–16% long-term growth range.
- Litigation and investigations create a financial or operating burden. Confirmed by: a company filing, court ruling, Department of Justice announcement or Texas Attorney General action disclosing damages, a settlement, charges, operating restrictions or a related reserve.
- Regulatory scrutiny limits Optum's acquisition growth. Confirmed by: a blocked or abandoned deal, or added conditions on the Amedisys transaction, citing antitrust concerns.
- The defensive sector rotation that lifted health care in late October reverses. Confirmed by: Health care lagging the S&P 500 over several sessions with no change in UnitedHealth's own guidance.
What it trades with
The shares trade with managed-care peers Humana, Elevance Health and CVS Health. They move together on CMS (Centers for Medicare & Medicaid Services) rate notices, star-rating changes and medical-cost trends. Humana's 6 November 2026 report helps on costs and hurts on competition: industry-wide cost relief lifts the group, while Humana's enrollment gains come partly at UnitedHealthcare's expense.
As a large health care holding, the stock also follows rotation between defensive and growth sectors. Defensive sectors trailed on 6 November 2026 and again on 11 November 2026 as growth and cyclical sectors led (Benzinga), yet the shares rose from $394.15 to $405.13 over that span. Washington policy risk is specific to the group: Medicare Advantage payment audits, the Senate inquiry into coverage terminations and antitrust criticism of vertically integrated insurers.
The evidence, claim by claim (8)
- The board amended the share repurchase program in November 2026 to authorize up to 50 million additional shares, with no established expiration date; 7.2 million shares remained authorized at 30 September 2026. UnitedHealth Group Q3 2026 Form 10-Q · as of
- UnitedHealth repurchased 3.4 million shares in Q3 2026 at an average of $410.01; shares outstanding were 896,022,611 at 30 October 2026. UnitedHealth Group Q3 2026 Form 10-Q · as of
- Q3 2026 adjusted EPS was $4.69 versus $2.92 a year earlier; 2026 guidance raised to adjusted EPS of at least $20.50 from $19.50–$20.00. UnitedHealth Group Q3 2026 earnings release, Form 8-K · as of
- Q3 2026 medical care ratio was 88.4% versus 89.9% a year earlier; Medicare Advantage membership fell 935,000 from year-end 2025. UnitedHealth Group Q3 2026 earnings release, Form 8-K · as of
- Nine-month 2026 favorable prior-year medical reserve development was $1,440 million, attributed to a favorable respiratory illness season. UnitedHealth Group Q3 2026 Form 10-Q · as of
- Surgery Partners' special committee rejected a nonbinding $28-per-share cash proposal, reported by Bloomberg as UnitedHealth's, citing regulatory risk and closing timeline; HealthSpan raised its agreed offer to $25. Becker's ASC, citing Bloomberg, 9 November 2026 · as of
- Lee Health said it will terminate its UnitedHealthcare participation agreement effective 31 December 2026. Company news, 9 November 2026 · as of
- Humana raised 2026 adjusted EPS guidance to at least $9.50 and said Medicare open-enrollment sign-ups are running ahead of plan. Healthcare Dive, 6 November 2026; Humana Q3 2026 Form 8-K · as of
Sources
- UNITEDHEALTH GROUP INC - Form 10-Q - FY2026 · sec.gov
- UNITEDHEALTH GROUP INC - Form 8-K - FY2026 · sec.gov
- Surgery Partners rejected UnitedHealth’s $28-a-share bid: Bloomberg · beckersasc.com
- Humana expects another year of Medicare Advantage membership growth in 2027 · healthcaredive.com ·
- UnitedHealth Rises 4% on Earnings Beat and Raised Full-Year Outlook; Humana Advances 2% · 247wallst.com ·
- Fintel
- When is UnitedHealth Group Earnings Q4 2026 2027? · days.to
Related · shared themes
AGL
agilon health
agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a…
BTSG
BrightSpring Health Services
BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy…
TDOC
Teladoc Health
Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing…
AMN
AMN Healthcare Services
AMN Healthcare Services is more likely to lag the S&P 500 because its fourth-quarter outlook cuts strike revenue to $5 million from $59…